Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Circassia Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 34.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Circassia Group. This N/A consensus rating has held steady for over two years.
Circassia Group Plc, a medical device company, focuses on the respiratory diagnostics and monitoring products in the United States, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It offers NIOX and NIOX VERO, a fractional exhaled nitric oxide measurement and monitoring products for use in asthma diagnosis and management. The company offers its products approximately in 50 countries through a network of distribution partners. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.